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SObjective: Sublobar resection (SR) is commonly used for patients considered high risk for lobectomy. Nonop-
erative therapies are increasingly being reported for patients with similar risk because of perceived lower mor-
bidity. We report 30- and 90-day adverse events (AEs) from American College of Surgeons Oncology Group
Z4032, a multicenter phase III study for high-risk patients with stage I non–small cell lung cancer.
Methods:Data from 222 evaluable patients randomized to SR (n¼ 114) or SRwith brachytherapy (n¼ 108) are
reported. AEs were recorded using the Common Terminology Criteria for Adverse Events, Version 3.0, at 30 and
90 days after surgery. Risk factors (age, percent baseline carbon monoxide diffusion in the lung [DLCO%], per-
cent forced expiratory volume in 1 second [FEV1%], upper lobe vs lower lobe resections, performance status,
surgery approach, video-assisted thoracic surgery vs open and extent, and wedge vs segmentectomy) were an-
alyzed using a multivariable logistic model for their impact on the incidence of grade 3 or higher (G3þ) AEs.
Respiratory AEs were also specifically analyzed.
Results:Median age, FEV1%, andDLCO%were similar in the 2 treatment groups. Therewas no difference in the
location of resection (upper vs lower lobe) or the use of segmental or wedge resections. There were no differences
between thegroupswith respect to ‘‘respiratory’’G3þAEs (30days: 14.9%vs19.4%,P¼ .35; 0–90days: 19.3%vs
25%, P ¼ .31) and ‘‘any’’ G3þAEs (30 days: 25.4% vs 30.6%, P ¼ .37; 0–90 days: 29.8% vs 37%, P ¼ .25).
Further analysis combined the 2 groups. Mortality occurred in 3 patients (1.4%) by 30 days and in 6 patients
(2.7%) by 90 days. Four of the 6 deathswere thought to be due to surgery.When considered as continuous variables,
FEV1% was associated with ‘‘any’’ G3þAE at days 0 to 30 (P ¼ .03; odds ratio [OR] ¼ 0.98) and days 0 to 90
(P ¼ .05; OR ¼ 0.98), and DLCO% was associated with ‘‘respiratory’’ G3þ AE at days 0 to 30 (P ¼ .03;
OR ¼ 0.97) and days 0 to 90 (P ¼ .05; OR ¼ 0.98). Segmental resection was associated with a higher incidence
of any G3þAE compared with wedge resection at days 0 to 30 (40.3% vs 22.7%; OR ¼ 2.56; P<.01) and days
0 to 90 (41.5% vs 29.7%; OR ¼ 1.96; P ¼ .04). The median FEV1% was 50%, and the median DLCO% was
46%. By using these median values as potential cutpoints, only a DLCO% of less than 46% was significantly as-
sociated with an increased risk of ‘‘respiratory’’ and ‘‘any’’ G3þAE for days 0 to 30 and 0 to 90.
Conclusions: In a multicenter setting, SR with brachytherapy was not associated with increased morbidity com-
pared with SR alone. SR/SR with brachytherapy can be performed safely in high-risk patients with non–small
cell lung cancer with low 30- and 90-day mortality and acceptable morbidity. Segmental resection was associ-
ated with increased ‘‘any’’ G3þAE, and DLCO% less than 46% was associated with ‘‘any’’ G3þAE and ‘‘re-
spiratory’’ G3þAE at both 30 and 90 days. (J Thorac Cardiovasc Surg 2011;142:1143-51)Earn CME credits at
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Abbreviations and Acronyms
ACOSOG ¼ American College of Surgeons
Oncology Group
AE ¼ adverse event
ASA ¼ American Society of
Anesthesiologists
CI ¼ confidence interval
CTC ¼ Common Terminology Criteria
DLCO ¼ carbon monoxide diffusion in the
lung
FEV1 ¼ forced expiratory volume in 1 second
NSCLC ¼ non–small cell lung cancer
OR ¼ odds ratio
SBRT ¼ stereotactic body radiation therapy
SR ¼ sublobar resection
SRB ¼ sublobar resection with
intraoperative brachytherapy
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Srecurrence rate after SR compared with lobectomy.1 One
approach that may reduce the incidence of local recurrence
is the addition of adjuvant brachytherapy.2-4 Z4032 is
a prospective randomized clinical trial by the American
College of Surgeons Oncology Group (ACOSOG) that
compares SR with intraoperative brachytherapy (SRB)
with SR alone. This study has recently completed accrual.
The primary outcome of interest of the study is 2-year local
control, and this end point will be reported when sufficient
follow-up becomes available. The current report examines
the incidence and severity of adverse events (AEs) occur-
ring at both 30 and 90 days after surgery from this multicen-
ter randomized prospective study. This is of particular
importance because nonoperative therapies, such as stereo-
tactic body radiation therapy (SBRT) and radiofrequency
ablation, are gaining increasing attention within the medical
community, even for patients who are candidates for oper-
ation.4,5 The toxicity profiles of the various lung cancer
therapies are important considerations when discussing
treatment options with patients. We report the incidence
and severity of AEs after SR in the high-risk population se-
lected for Z4032.
MATERIALS AND METHODS
Eligible patients for this study included patients with stage I lung
cancers 3 cm or less in maximum diameter (ie, stage IA or the subset of
stage IB with visceral pleural involvement) on preoperative computed to-
mography scan. Patients were defined as high risk for lobectomy if they
met at least 1 major criterion or 2 minor criteria as described in Table 1.
In addition to meeting these criteria, patients had to be evaluated by an
ACOSOG-approved thoracic surgeon and considered not to be a candidate
for lobectomy or to be too high risk for any form of pulmonary resection.
Patients considered medically inoperable (but who met these criteria) were
usually referred for nonoperative therapies, such as radiofrequency abla-
tion or SBRT. We did not record the details of screened patients who1144 The Journal of Thoracic and Cardiovascular Surmet the major and minor criteria described above who were not offered
participation in this study. To confirm that patients did not have nodal in-
volvement, all suspicious lymph nodes seen on positron emission tomog-
raphy or computed tomography scan required biopsy by mediastinoscopy,
endobronchial ultrasound, or sampling at the time of resection. SR in-
cluded wedge or segmental resection and could be performed by video-
assisted thoracic surgery or thoracotomy. Two methods of brachytherapy
were allowed.6,7 The method used was at the discretion of the treating
surgeon. In the first technique, polyglactin sutures containing 125I seeds
(Oncura, Inc, Princeton, NJ) were placed parallel to and 5 mm away
from the staple line on each side of the resection margin. The suture
strands were fixed to the lung surface with several 3.0 silk or polyglactin
sutures placed 1 to 2 cm apart. With the second brachytherapy
technique, a polyglycolic mesh implant was created during the
procedure. The same 125I suture strands were woven into a piece of
Vicryl mesh. The strands were placed at 1-cm intervals. The mesh was
then sutured over the staple line. The dosimetry goal of the brachytherapy
was to deliver 100 Gy at 5 to 7 mm along the central axis of the resection
margin.
AEs were recorded using the Common Terminology Criteria (CTC) for
Adverse Events Version 3.0.8 The CTC is a broad classification of AE with
several defined categories.Within each category, AEs are listed and accom-
panied by a description of severity (grade). Grade 1 is mild, grade 2 is mod-
erate, grade 3 is severe, grade 4 is life-threatening or disabling AE, and
grade 5 is death related to the AE.
AEs were analyzed at 0 to 30 days and again at 0 to 90 days. For the
purpose of this report, we limit discussion to grade 3 and higher (3þ)
AE. Because this group was considered high risk primarily on the basis
of lung function, 2 groups of AE were studied: ‘‘any AE’’ or ‘‘respira-
tory AE’’, where ‘‘respiratory AE’’ included adult respiratory distress
syndrome, aspiration, bronchospasm, bronchostenosis, dyspnea, hyp-
oxia, pleural effusion, pneumonitis, chest tube drainage or leak, pro-
longed intubation, pulmonary-other, and pneumonia as defined by the
CTC.
All patients provided written informed consent before trial enrollment
in accordance with applicable guidelines. At each participating site, insti-
tutional review board approval was obtained in accord with an assurance
filed with and approved by the US Department of Health and Human
Services.Statistical Analysis
Chi-square tests for categoric variables and Wilcoxon rank-sum tests
for continuous variables were used to compare the baseline patient char-
acteristics between the SR and the SRB arms. We compared the 2 treat-
ment arms for the incidence of any grade 3þ AE and any grade 3þ
respiratory AE using a Fisher exact test. Risk factors for AEs (age,
baseline carbon monoxide diffusion in the lung [DLCO]%, and forced
expiratory volume in 1 second [FEV1]% considered as continuous vari-
ables, upper lobe vs lower lobe resection, and performance status) were
analyzed using a multivariable logistic model for any grade 3þ and
grade 3þ respiratory AEs at 0 to 30 days and 0 to 90 days. In addition
to these factors, surgery extent (wedge vs segmentectomy) and type
(thoracotomy vs video-assisted thoracic surgery) were also considered
for any grade 3þAEs outcomes at 0 to 30 and 0 to 90 days. Odds ratios
(ORs) and 95% confidence intervals (CIs) are reported, where the OR
estimates for a continuous covariate correspond to a 1-unit increase.
Optimal cutpoints were therefore explored to define the high-risk versus
low-risk categories for the baseline DLCO% and FEV1% using data-
dependent methods (mean or median) and outcome-based approaches
(graphic diagnostic plots and the minimum P value approach).9 Subse-
quently, univariable logistic regression models using the categorized
DLCO% and FEV1% were explored. In addition, the entry criteria
used to define the high-risk subset were explored further by first analyz-
ing patients eligible by at least 2 minor criteria and by includinggery c November 2011
TABLE 1. Major and minor eligibility criteria for Z4032 trial*
SRy (N ¼ 114) SRBy (N ¼ 108)
Major criteria
1. FEV1  50% predicted 67 (58.8%) 49 (45.4%)
2. DLCO  50% predicted 72 (63.2%) 74 (68.5%)
Minor criteria
1. Age  75 y 43 (37.7%) 42 (38.9%)
2. FEV1 51%-60% predicted 18 (15.8%) 25 (23.1%)
3. DLCO 51%-60% predicted 19 (16.7%) 19 (17.6%)
4. Pulmonary hypertension (defined as pulmonary artery systolic pressure
>40 mm Hg) as estimated by echocardiography or right heart catheterization
4 (3.5%) 1 (0.9%)
5. Poor left ventricular function (defined as ejection fraction  40%) 9 (7.9%) 3 (2.8%)
6. Resting or exercise arterial PO2  55 mm Hg or SPO2 88% 5 (4.4%) 6 (5.6%)
7. PCO2>45 mm Hg 3 (2.6%) 3 (2.8%)
8. Modified Medical Research Council Dyspnea Scale 3 31 (27.2%) 17 (15.7%)
*Eligible patients must have met 1 major or 2 minor criteria. In addition, patients must be deemed not to be candidate for a lobectomy by an American College of Surgeons
Oncology Group–approved thoracic surgeon. yOne patient may have multiple criteria.
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risk factors in univariable logistic regression models for all the end
points considered.RESULTS
Z4032 met its target accrual and was permanently closed
to enrollment on January 22, 2010. A total of 224 patients
were registered. One patient from the SR arm had the inter-
vention at a hospital not approved by the institutional re-
view board hospital and was deemed not evaluable. One
patient randomized to the SRB group did not have surgery
and was also not evaluable. A total of 222 patients
(SR ¼ 114; SRB ¼ 108 patients) were eligible for analysis
(Figure 1).
Table 2 depicts the patient characteristics for the 2
groups. There were no significant differences between the
2 intervention groups in baseline characteristics, except
American Society of Anesthesiologists (ASA) class, for
which a higher percentage of the SR group was classified
as ASA III/IV. The median age, FEV1%, and DLCO%
were similar for the 2 groups.FIGURE 1. Patient consort diagram.
The Journal of Thoracic and CarThirty- and Ninety-Day Mortality: Sublobar
Resection Versus Sublobar Resection With
Brachytherapy
There were no significant differences between the SR and
SRB groups with respect to 30- and 90-day mortality (grade
5 AE). Three deaths (1.4%) occurred within 30 days. One
patient (0.9%) in the SR group died of cardiopulmonary ar-
rest. Two patients (1.9%) in the SRB group died of cerebro-
vascular accident and pulmonary embolus. By 90 days, an
additional 3 deaths (total, 6; 2.7%) had occurred. Two pa-
tients (1.8%) were in the SR group and included cancer pro-
gression in the 1 patient found to have N2 disease on
pathologic staging and a fatal cardiac event in 1 patient.
One patient (0.9%) in the SRB group died of sepsis. Four
of the 6 deaths occurring by 90 days were thought to be at-
tributable to the surgery performed.
Thirty- and Ninety-Day Adverse Events: Sublobar
Resection Versus Sublobar Resection With
Brachytherapy
Median length of stay was 5 days for each group
(P ¼ .33). At 0 to 30 days, grade 3þAE occurred in 29 pa-
tients (25.4%) in the SR group compared with 33 patients
(30.6%) in the SRB group (P ¼ .37). Grade 4þAEs were
also similar, occurring in 8 patients (7%) in the SR group
compared with 8 patients (7.4%) in the SRB group
(P ¼ .90). In terms of respiratory AE, grade 3þ AE and
grade 4þAE occurred in 17 patients (14.9%) and 21 pa-
tients (19.4%) in the SR group (P ¼ .35), and 4 patients
(3.5%) and 4 patients (3.7%) in the SRB group (P ¼
.93), respectively. The most common grade 3þAEs (defined
as occurring in  5% patients within each arm) were hem-
orrhage (4.1%; 3 in the SR group and 6 in the SRB group),
dyspnea (8.6%; 11 in the SR group and 8 in the SRB group),
and hypoxia (6.3%; 5 in the SR group and 9 in the SRB
group).diovascular Surgery c Volume 142, Number 5 1145
TABLE 2. Baseline patient characteristics
SR
(N ¼ 114)
SRB
(N ¼ 108) P value*
Age, y .37y
Median (range) 70 (49-85) 72 (50-87)
Sex .72
Female 65 (57%) 59 (55%)
Male 49 (43%) 49 (45%)
Ethnicity .16
Hispanic or Latino 0 (0%) 2 (1.9%)
Not Hispanic or Latino 104 (91%) 91 (84%)
Unknown 10 (9%) 15 (14%)
Race .42
White 107 (93.9%) 103 (95.4%)
Black 7 (6.1%) 4 (3.7%)
Unknown 0 (0%) 1 (0.9%)
Baseline performance status .56
0 20 (17.5%) 25 (23.1%)
1 66 (57.9%) 60 (55.6%)
2 28 (24.6%) 23 (21.3%)
T stage .12
T1 114 (100%) 104 (96.3%)
T2 0 (0%) 3 (2.8%)
T3 0 (0%) 1 (0.9%)
M stage NA
M0 114 (100%) 108 (100%)
N stage .37
N0 113 (99.1%) 107 (99.1%)
N1 0 (0%) 1 (0.9%)
N2 1 (0.9%) 0 (0%)
Surgery in upper lobe .07
No 38 (33.3%) 49 (45.4%)
Yes 76 (66.7%) 59 (54.6%)
Surgery type
VATS 79 (69.3%) 65 (60.2%) .16
Thoracotomy 35 (30.7%) 43 (39.8%)
Surgery extent .29
Segmentectomy 38 (33.3%) 29 (26.9%)
Wedge resection 76 (66.7%) 79 (73.1%)
ASA class (III/IV vs I/II)
on surgery dayz
.02
I/II 10 (8.8%) 21 (19.8%)
III/IV 104 (91.2%) 85 (80.2%)
Baseline DLCO% .36y
N 111 106
Median (range) 47 (18-97) 44 (8-137)
Baseline FEV1% .25y
N 114 107
Median (range) 48 (22-117) 53 (25-110)
VATS, Video-assisted thoracic surgery; NA, not available. *Chi-square test.
yWilcoxon rank-sum test. zExcludes 2 SRBs with missing data.
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(29.8%) in the SR group and 40 patients (37%) in the
SRB group (P ¼ .25). Grade 4þ events were also similar
(P ¼ .71), occurring in 10 patients (8.8%) in the SR group
and 8 patients (7.4%) in the SRB group. In terms of1146 The Journal of Thoracic and Cardiovascular Surrespiratory AE, grade 3þAE and grade 4þAE occurred in
22 patients (19.3%) and 27 patients (25%), and 6 patients
(5.3%) and 4 patients (3.7%) in the SR and SRB groups,
respectively (P ¼ .31; P ¼ .58). The most common grade
3þ AEs (defined as occurring in 5% patients within
each arm) were the same as those reported for 0 to 30
days, with an exception of increasing reports of dyspnea oc-
curring in 29 patients (13.1%, 14 in the SR group and 15 in
the SRB group).
Twelve patients (9 in the SR group and 3 in the SRB
group) had poor left ventricular function at study entry.
There was no association between ASA class and poor
left ventricular function (Fisher exact P ¼ 1.0). Logistic re-
gression analysis considering ASA class and treatment arm
as predictors of grade 3þcardiovascular AEs showed no sig-
nificant effect of ASA class (days 0–30: P ¼ .92; OR, 0.92;
95%CI, 0.19–4.45; days 0–90: P¼ .94; OR, 1.06; 95% CI,
0.22–5.02).
Thirty- and Ninety-Day Adverse Events: All Patients
The 2 groups were therefore combined for further analy-
ses. We found that patients based on ‘‘any 2 minor criteria’’
and ‘‘at least FEV1% and DLCO% as minor criteria’’ were
not significant predictors of AE outcomes. In amultivariable
model of FEV1% (considered as a continuous variable)
without DLCO%, FEV1% was associated with any grade
3þ AE at days 0 to 30 (P ¼ .04; OR, 0.98; 95% CI,
0.97–1.00) and respiratory grade 3þ AE at days 0 to 30
(P ¼ .04; OR, 0.98; 95% CI, 0.96–1.00) and days 0 to 90
(P ¼ .03; OR, 0.98; 95% CI, 0.96–1.00). Likewise, when
DLCO% (as a continuous variable) was considered in
a multivariable model without FEV1%, it was associated
with respiratory grade 3þ AE at days 0 to 30 (P ¼ .02;
OR, 0.97; 95% CI, 0.95–1.00) and days 0–90 (P ¼ .04;
OR, 0.98; 95% CI, 0.96–1.00).
Table 3 shows the multivariable model results when
FEV1% and DLCO% were considered together as contin-
uous variables. For days 0 to 30 and 0 to 90, only FEV1%
was significantly associated with any grade 3 þ AE.
DLCO% was significantly associated with respiratory
grade 3þAE for days 0 to 30 and 0 to 90.
In the case of any grade 3þAE, in addition to the risk fac-
tors already considered, surgery extent and type were also
explored. Surgery extent was significantly associated with
any grade 3þAE, with events occurring in patients undergo-
ing segmentectomy compared with wedge resection at days
0 to 30 (segment ¼ 40.3%, wedge ¼ 22.7%) and days 0 to
90 (segment ¼ 41.8%, wedge ¼ 29.7%).
The median FEV1% for all patients was 50% (compared
with 55% for any grade 3þ and 53% for any respiratory
grade 3þ using the outcome-oriented approaches), and the
median DLCO% for all patients was 46% (compared
with 42% and 44% for any grade 3þAE and grade 3þrespi-
ratory AE). Thus, we report the results using the mediangery c November 2011
TABLE 3. Results frommultivariable logistic regression models using forced expiratory volume in 1 second and carbon monoxide diffusion in the
lung as continuous variables
Model outcome Predictors Odds ratio (95% CI) P value
Any grade 3þAE day 0-30 Upper lobe: yes vs no 0.68 (0.35-1.30) .24
Age (continuous) 1.03 (0.99-1.07) .18
Baseline DLCO% (continuous) 0.98 (0.96-1.00) .09
Baseline FEV1% (continuous) 0.98 (0.96-1.00) .03
PS: 2 vs 0-1 0.90 (0.42-1.92) 0.78
Surgery type: thoracotomy vs VATS 1.03 (0.53-2.00) 0.94
Surgery extent: wedge vs segmentectomy 0.39 (0.20-0.75) <.01
Any grade 3þAE day 0-90 Upper lobe: yes vs no 0.75 (0.41-1.39) 0.37
Age (continuous) 1.01 (0.97-1.04) 0.72
Baseline DLCO% (continuous) 0.99 (0.97-1.01) 0.25
Baseline FEV1% (continuous) 0.98 (0.97-1.00) 0.05
PS: 2 vs 0-1 0.98 (0.48-1.99) 0.96
Surgery type: thoracotomy vs VATS 0.87 (0.46-1.64) 0.67
Surgery extent: wedge vs segmentectomy 0.51 (0.27-0.96) 0.04
Grade 3þ respiratory AE day 0-30* Upper lobe: yes vs no 0.58 (0.27-1.23) 0.16
Age (continuous) 1.01 (0.97-1.06) 0.52
Baseline DLCO% (continuous) 0.97 (0.95-1.00) 0.03
Baseline FEV1% (continuous) 0.98 (0.96-1.00) 0.07
PS: 2 vs 0-1 1.01 (0.42-2.47) 0.98
Grade 3þ respiratory AE day 0-90* Upper lobe: yes vs no 0.59 (0.29-1.18) 0.14
Age (continuous) 1.00 (0.96-1.04) 0.97
Baseline DLCO% (continuous) 0.98 (0.96-1.00) 0.05
Baseline FEV1% (continuous) 0.98 (0.96-1.00) 0.06
PS: 2 vs 0-1 1.15 (0.52-2.53) 0.74
VATS, Video-assisted thoracic surgery; PS, performance status. *Surgery type/extent not considered because of limited number of events.
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categories based on baseline FEV1% and DLCO% (Table
4). An FEV1 of less than 50% was not associated with an
increased risk of grade 3þ respiratory or any AE. However,
DLCO less than 46% was significantly associated with an
increased risk of respiratory and any grade 3þAE for days
0 to 30 and 0 to 90 (Table 4). Of note, the results were sim-
ilar when using the other potential cutpoints for DLCO%
and FEV1%.
DISCUSSION
Pulmonary resection is generally considered the gold
standard for patients with early-stage NSCLC. For patientsTABLE 4. Results from the logistic regression models using median forced
lung as cutpoints
Model outcome Predictors
Grade 3þ respiratory AE day 0-30 DLCO%:<46 vs 46
Grade 3þ respiratory AE day 0-90 DLCO%:<46 vs 46
Any grade 3þAE day 0-30 DLCO%:<46 vs 46
Any grade 3þAE day 0-90 DLCO%:<46 vs 46
Grade 3þ respiratory AE day 0-30 FEV1%:<50 vs 50
Grade 3þ respiratory AE day 0-90 FEV1%:<50 vs 50
Any grade 3þAE day 0-30 FEV1%:<50 vs 50
Any grade 3þAE day 0-90 FEV1%:<50 vs  50
The Journal of Thoracic and Carwith impaired pulmonary function, the risks of surgical re-
section are a significant concern. With the increasing avail-
ability of nonoperative approaches, it is imperative that
physicians have a good understanding of the relative risks
of the various therapies available. The CTC classification
is a useful tool that can be used to compare procedure
therapy-related complications. This is the standard ap-
proach used in most oncologic studies, but it is rarely used
in surgical studies. The availability of a grading system is
also helpful, because many complications commonly re-
ported in surgical series could be considered minor and
less than the usual grade 3þreported. One example is atrial
fibrillation, which was reported as 9.3% in one series ofexpiratory volume in 1 second and carbon monoxide diffusion in the
Incidence of AE (%) OR (95% CI) P value
11.3% vs 5.4% 2.41 (1.14-5.09) .02
14% vs 7.2% 2.34 (1.19-4.59) .01
17.1% vs 10.4% 2.01 (1.09-3.68) .02
19.4% vs 13.1% 1.82 (1.03-3.24) .04
9.5% vs 7.7% 1.29 (0.64-2.61) .48
12.6% vs 9.5% 1.46 (0.77-2.78) .24
15.3% vs 12.6% 1.31 (0.73-2.36) .37
18.5% vs 14.9% 1.40 (0.80-2.46) .24
diovascular Surgery c Volume 142, Number 5 1147
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SSR.10 By CTC criteria, atrial fibrillation would be consid-
ered grade 3 if this was incompletely controlled by medical
therapy or required a device. An example of another compli-
cation, which may be over- or underreported, is atelectasis.
Grade 2 atelectasis would include the use of bronchoscopy,
suctioning, or chest physiotherapy for control. Grade 3 atel-
ectasis would require operative intervention, such as a stent
or laser. In the STS General Thoracic Database, atelectasis
requiring bronchoscopy is classified as a complication with-
out any consideration given to severity.
Our series demonstrated an overall incidence of grade 3þ
complications of 27.9% during the 0- to 30-day period.
Specifically, grade 3 complications occurred in 19.4% of
patients, grade 4 complications occurred in 5.9% of pa-
tients, and grade 5 (death) occurred in 1.4% of patients.
These results provide a valuable benchmark for current-
day morbidity and mortality after SR in these high-risk pa-
tients. In contrast with these results, the recent Radiation
Therapy and Oncology Group Phase 2 study of SBRT re-
ported a 12.7% incidence of grade 3 AE, a 3.6% incidence
of grade 4 AE, and no grade 5 AE.11 Morbidity was less
with this nonoperative intervention, although oncologic
comparisons still need to be determined. A key factor to
consider is that the patient groups in the 2 studies may not
be directly comparable. The best comparison between these
2 therapies would be a randomized study taking similar-risk
patients, using similar definitions of outcome for the entire
patient cohort. This is being done by the ACOSOG, which is
partnering with the Radiation Therapy and Oncology Group
in a phase III study that will compare SBRT with SR for
high-risk patients, using the same eligibility criteria as
Z4032. This phase III study (Z4099) will be critical to
help determine appropriate patient selection for operative
or nonoperative therapies.
This current report provides information on 90-day out-
comes for our patients. Most surgical series and even the
Society of Thoracic Surgeons Database report outcomes
only to 30 days. This might lead to underreporting of poor
outcomes in patients who have complications resulting in
transfer to long-term care facilities and who sustain grade
5 AE outside of the hospital. Our 90-day outcomes demon-
strated a 2.7% mortality at 90 days, which is acceptable
considering the greater than average risk of these surgical
patients.
Bryant and colleagues12 recently published 30- and 90-
day outcomes from a large retrospective single institution
series. Their series included 1845 patients with variable op-
erative risk and patients treated with both lobar and SRs.
Discharge mortality was 3.1%. An additional 1% died after
discharge, within 30 days, and an additional 2.5% died
within 90 days. In patients who died before 30 days, the
most common cause of mortality was a pulmonary event,
with risk factors being older age, occurrence of a postoper-
ative event, greater hospital length of stay, and1148 The Journal of Thoracic and Cardiovascular Surpneumonectomy. In patients who died between 30 and 90
days, the most common cause of mortality was natural
causes, which included cancer progression.
ACOSOG previously reported morbidity and mortality in
a large randomized study comparing lymph node resection
with lymph node dissection.13 In that study involving 1023
standard-risk, operable patients, toxicity grade was not
reported. Complications occurred in 38% of patients, and
operative mortality was 1.37%. The most common compli-
cation was atrial arrhythmias (14%). Respiratory complica-
tions occurred in 7% of the patients in that large series.
We are unable to determine risk factors for 90-day mor-
tality, because only a few grade 5 events occurred in our se-
ries. However, we evaluated the risk factors for grade 3þAE
at both 30 and 90 days. Segmentectomy is generally consid-
ered to be preferable to wedge resection as a superior onco-
logic procedure.14 Segmental resections are more complex,
and in our study this is reflected in the higher incidence of
any grade 3þAE at days 0 to 30 and 0 to 90.
Although FEV1% was a significant predictor when con-
sidered as a continuous variable for any grade 3þAE at both
30 and 90 days, with higher values being protective, it was
not significant when considered as a categoric variable.
DLCO less than 46% was predictive of any grade 3þAE
and respiratory grade 3þAE at both 30 and 90 days, suggest-
ing that this might be a group who may have better out-
comes with nonoperative therapies. Clearly, the 95% CI
for these OR estimates include 1.00, indicating that these re-
sults are suggestive but not definitive. This will be investi-
gated further in Z4099.
DLCO has been demonstrated in other studies to be an in-
dependent predictor of mortality even with otherwise nor-
mal spirometry. Ferguson and colleagues15 reported
results from an institutional database with 1046 patients.
Within this series, there were 558 patients without chronic
obstructive pulmonary disease. Postoperative predicted
DLCO was the single strongest predictor of pulmonary
morbidity and operative mortality in patients with and with-
out chronic obstructive pulmonary disease in their study.CONCLUSIONS
This randomized, prospective study demonstrates that
there is no increase in morbidity or mortality with the addi-
tion of intraoperative brachytherapy to SR. In a cohort of
high-risk patients, SR (with or without brachytherapy) can
be undertaken with low mortality and acceptable morbidity.
Segmental resection was associated with more ‘‘any’’ grade
3þAEs compared with wedge resection. Low pretreatment
DLCO% (<46) was an adverse predictor of respiratory and
‘‘any’’ grade 3þAEs.
The authors thank the ACOSOG staff, in particular the leader-
ship of Heidi Nelson and David Ota, for assistance in the develop-
ment of this manuscript; all of the investigators and their sitegery c November 2011
Fernando et al General Thoracic Surgery
G
T
Sresearch teams; and the brave patients with NSCLC and their care-
givers who participated in this study.
References
1. Ginsberg RJ, Rubenstein LV. Randomized trial of lobectomy versus limited re-
section for T1NONon-small cell lung cancer. Ann Thorac Surg. 1995;60:615-23.
2. Fernando HC, Santos RS, Benfield JR, et al. Lobar and sublobar resection with
and without brachytherapy for small stage Ia non-small cell lung cancer. J
Thorac Cardiovasc Surg. 2005;129:261-7.
3. VoynowG, Heron DE, Lin CJ, et al. Intraopeative (125)I Vicryl mesh brachyther-
apy after sublobar resection for high-risk stage I non-small cell lung cancer. Bra-
chytherapy. 2005;4:278-85.
4. Timmerman RD, Park C, Kavanagh BD. The North American experience with
stereotactic body radiation therapy in non-small cell lung cancer. J Thorac On-
col. 2007;2(Suppl 3):S101-12.
5. Dupuy DE, DiPetrillo T, Gandhi S, et al. Radiofrequency ablation followed by
conventional radiotherapy for medically inoperable stage I non-small cell lung
cancer. Chest. 2006;129:738-45.
6. Lee W, Daly BDT, DiPetrillo TA, et al. Limited resection for non-small cell lung
cancer: observed local control with implantation of I-125 brachytherapy seeds.
Ann Thorac Surg. 2003;75:237-43.
7. d’Amato TA, GallowayM, Szydlowski G, et al. Intraoperative brachytherapy fol-
lowing thoracoscopic wedge resection of stage I lung cancer. Chest. 1998;114:
1112-5.
8. Common Terminology Criteria for Adverse Events (CTCAE) Version 3. Wash-
ington, DC: US Department of Health and Human Services, National Institutes
of Health, National Cancer Institute; 2003.
9. Williams BJ, Mandrekar JN, Mandrekar SJ, Cha SS, Furth AF. Finding optimal
cutpoints for continuous covariates with binary and time-to-event outcomes.
Technical Report, Division of Biostatistics, Mayo Clinic. June 2006;79.
10. Shuchert MJ, Pettiford BL, Keeley S, et al. Anatomic segmentectomy in the treat-
ment of stage I non-small cell lung cancer. Ann Thorac Surg. 2007;84:926-33.
11. Timmerman R, Paulus R, Galvin J, et al. Sterotactic body radiation therapy for
inoperable early stage lung cancer. JAMA. 2010;303:1070-6.
12. Bryant AS, Rudemiller K, Cerfolio RJ. The 30- versus 90-day operative mortality
after pulmonary resection. Ann Thorac Surg. 2010;89:1717-23.
13. Allen MS, Darling GE, Pechet TTV, et al. Morbidity and mortality of major pul-
monary resections in patients with early-stage lung cancer: Initial results of the
randomized prospective ACOSOG Z0030 Trial. Ann Thorac Surg. 2006;81:
1013-20.
14. El-Sherif A, Fernando HC, Santos R, et al. Margin and local recurrence after sub-
lobar resection of non-small cell lung cancer. Ann Surg Oncol. 2007;14:2400-5.
15. Ferguson MK, Vigneswaren WT. Diffusing capacity predicts morbidity after
lung resection in patients without obstructive lung disease. Ann Thorac Surg.
2008;85:1158-64.Discussion
Dr Erino Rendina (Rome, Italy). Your results are remarkable,
but the remarkability in terms of AEs also depends on the selection
of your patients. In fact, I think when the patients have an FEV1 of
approximately 50% and no other exclusion criteria, lobectomy
could still be done, and this remains the gold standard because
it’s also preserving the quality of life. Nonetheless, looking specif-
ically at the data you presented here, I agree with your conclusion
that SR can be undertaken safely in high-risk patients with NSCLC
with acceptable 30- and 90-day mortality and morbidity.
In your article, you stated that SR included wedge resection or
segmental resection and could be performed by video-assisted tho-
racic surgery (VATS) or thoracotomy. Potential benefits of thora-
coscopic resections have been reported that include equivalent
oncologic outcomes to those of open surgery and less morbidity.
Do you know what percentage of resections were VATS or open
in your group, and did you look at whether it could have an impact
on the results?The Journal of Thoracic and CarDr Fernando. I’m going to take your first point addressing the
50% FEV1. Our criteria were broad. They included patients who
may have had restrictive disease and cardiac disease. One issue
to point out is that as a surgeon you may see a patient who has
an FEV1 of 45% in whom you would definitely perform a lobec-
tomy, but you may also see a patient with an FEV1 of 55% who
clearly would not tolerate a lobectomy because of other things.
So our criteria were broad, but would still allow the thoracic sur-
geon to look at each patient and make an assessment that SR
was the optimal approach for a specific patient, and allow enroll-
ment in the study.
The second question was with the VATS versus thoracotomy.
Some 65% of these patients in both groups actually had a thoraco-
scopic resection. It was interesting that most of the resections per-
formed were thoracoscopic. I don’t know the breakdown in terms
of wedge and segment, and whether more segments were done
with one approach or the other. That is planned for another analy-
sis. Last year we presented the preliminary data on 150 patients,
looking at 30- and 90-day impact on pulmonary function test,
and we saw no difference between the VATS and open groups in
that particular analysis.
Dr Rendina. You stated that 2 methods of brachytherapy were
allowed in your study. Was your choice to use one method or the
other dictated by any specific reason?
Dr Fernando. This was really at the discretion of the surgeon.
We reviewed the techniques that were out there at the time the
study was developed, and there was no data to support one over
the other. So we left the decision to the surgeon. We have not an-
alyzed the impact of the brachytherapy approach specifically on
complications. There has been a brachytherapy quality control
analysis that was presented at ASTRO by one of the radiation on-
cologists on the protocol, and this looked more at the ability to de-
liver the dose that was planned, and, again, I don’t know the
differences between the 2 groups.
Dr Rendina. Are there particular precautions that have to be
taken with manipulating this material?
Dr Fernando. I wear lead when I do these procedures. When
I’m actually sewing these in place, I don’t tie down directly onto
the lung. I tie extracorporeally when placing these by VATS or
take a clip applier and use the clips as my knot rather than trying
to tie with my hand directly onto the mesh.
Dr Rendina. In your report, the 90-day outcomes demonstrated
a 2.7% mortality, which is absolutely acceptable considering the
greater than average risk of these patients. However, I noticed
that 1 death in the SR group included cancer progression, which
is pretty surprising for patients with stage I disease. Do you have
an explanation for this? Do you want to comment on this issue?
Dr Fernando. I don’t know the results of that. As I said, we’re
planning on presenting the survival and recurrence data when this
matures. I don’t know whether the patient truly had a recurrence or
occult metastatic disease that we didn’t know about at the time,
and the patient presented a month or so after resection with this.
That needs to be looked at a bit more carefully.
Dr Rendina. Thank you.
Dr ThomasWaddell (Toronto, Ontario, Canada). I want to fol-
low up on one point that Dr Rendina made and ask you to talk a bit
about the new study that is going to compare this type of treatment
with SBRT. This morning we heard Dr Puri talk about an analysis,diovascular Surgery c Volume 142, Number 5 1149
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SBRTand surgery were very different. Overall, 7%mortality in the
surgery group and zero in the SBRT group seems to favor SBRT.
So I think that the subject of who should enter these trials is crit-
ical. I take your point that you need to have an accruing trial,
but I think defining what we mean by high risk is very important.
How can we use this information to think about the next trial, that
is, to say how do we define a high-risk person? I would say a 30-
day mortality of 1.4 is not that different than what Dr Allen re-
ported based on Z0030 for lobectomy. So I would come back to
Dr Rendina’s point, that I’m not so sure these patients are really
as high risk as you would have us believe, and certainly they are
not as high risk as the patients who have been up to now dealt
with by SBRT.
Dr Fernando. Actually, I would say that some of those
patients treated with SBRT are probably good-risk patients as
well, who are getting to the radiation oncologists without the
benefit of seeing a surgeon and in some cases may have refused
surgery. Every patient in this study was seen by an ACOSOG-ap-
proved thoracic surgeon, which meant they were board-certified
in cardiothoracic surgery, with 50% of their practice devoted to
thoracic surgery, or members of the General Thoracic Club, and
they had to pass a credentialing test to be involved in this. Every
patient had to be seen by a thoracic surgeon who decided if the
patient was high risk for lobectomy. We can all say that we oper-
ate on patients with an FEV1 of 40% or 35% and sometimes per-
form lobectomies on those patients. Every patient has a specific
set of comorbidities that allows you as a surgeon to make that
judgment. If we had made this trial restrictive and only taken
30% or less or 40% or less, or whatever number we would have
chosen, it would have taken twice as long to accrue to this study.
This next study is going to be looking at patients with exactly the
same set of inclusion criteria. Every patient will have to be seen
by a thoracic surgeon. The only difference is that the tissue diag-
nosis will have to be made up front so we avoid the problem that
other SBRT studies have made by including patients who don’t
have a tissue diagnosis. We are going to have common definitions
of outcome, including complications and recurrence, because
there are also differences in recurrence rates between the SBRT
and surgical studies that can be explained in part by differences
of definition. So this next study will give us our best chance to
see what the role of surgery is for this group of patients.
Dr Todd Demmy (Buffalo, NY). Do you have any data on the
discharge independence of these patients? I think that’s the other
element that we have to capture when we start thinking about com-
parative studies. It was already stated this morning in the lecture
that if it’s less invasive, it tends to win, so SBRT already has an
edge on that. Are you going to collect data to show that these pa-
tients don’t go to nursing homes and end up with a lot of repeat
visits beyond the 90-day mortality end point? Are you going to
look at these functional and quality of life outcomes?
Dr Fernando. With Z4032, we didn’t include that as an end
point, but the Z4099 study, which opened last week, the case report
forms specifically ask those questions about where the patient
goes, home or to an acute care facility. I think that is an important
outcome to measure.
Dr Scott Swanson (Boston, Mass). That was an outstanding
presentation, and you are to be commended for doing this trial1150 The Journal of Thoracic and Cardiovascular Surbecause it’s critical for us as surgeons. The outcome data are amaz-
ing, really good mortality and morbidity.
Do you have any data on lymph node sampling? I know that’s
not the point of this study, but as we go forward comparing with
SBRT, certainly that is a major difference. Was that part of this
study?Was there any requirement?Doyouhave anydetails on that?
Dr Fernando. Lymph node counts were not collected in our
case report forms. We are planning an analysis comparing VATS
and thoracotomy, which Michael Kent from Beth Israel Deaconess
is going to lead. We are going to be looking at all the operative and
path notes that are available as part of the source data, even though
that specific information was not collected in the case report forms
up front. We hope to have that information within the next 6
months to present to everybody when we look at the differences
for the patients who had VATS or thoracotomy.
Dr Servet Bolukbas (Wiesbaden, Germany). During the eval-
uation of your patients, there is a high possibility of detecting
chronic obstructive pulmonary disease. Were there any attempts
to treat those patients with drugs, to send them to pulmonary re-
habilitation to improve FEV1, to switch the patients from high to
normal risk?
Dr Fernando. Not specifically in this group. I think the differ-
ence between these patients and patients in the National Emphy-
sema Treatment Trial study, for example, is that you don’t really
have the luxury of 6 weeks to perform pulmonary rehabilitation
in these patients. You want to try and deal with the cancer within
a reasonable time frame. So we have not been putting patients
through pulmonary rehabilitation before resecting lung cancers.
Dr Bolukbas. But in stage I, I think there is time to do pulmo-
nary rehabilitation for 6 weeks.
Dr Fernando. Perhaps.
Dr Joel Cooper (Philadelphia, Pa). Just for point of emphasis, I
want to recapitulate. I am concerned with people labeling an FEV1
of 50% as defining ‘‘high risk’’ because it’s not, and the pulmonary
physicians and radiotherapists are going to use that definition to in-
dicate that patients are high risk when they are not, and that will
turn influence selection criteria for these trials. Remember, chronic
obstructive pulmonary disease is a couple of pulmonary dis-
eases—airways disease and emphysema, 2 very different condi-
tions, both with very different risk factors. The FEV1 can be
25%with no emphysema because it’s due to small airways disease,
or it can be due to loss of elastic recoil, namely, emphysema. Dif-
fusing capacity is a little different. A person with an FEV1 of 25%
whose computed tomography scan doesn’t show much emphy-
sema and whose diffusing capacity is 35% to 40% is not a particu-
larly high-risk patient for a lobectomy if you choose well. In
summary, FEV1 alone does not adequately define risk for resection
and potentially does a great disservice to patients. Furthermore, it
ignores the importance of the surgeon’s judgment and experience
in selecting appropriate patients for surgical resection.
Dr Fernando. I will say that the American College of Chest
Physicians in their guidelines used 80% for their cutoff for what
defined high or low risk, and they also recommended more inva-
sive evaluation of those patients, including split-lung ventilation/
perfusion scans, which seems kind of ridiculous for patients with
such a high FEV%. That’s something that Frank Detterbeck is in-
vestigating in another study. I also think there is a real problem
with trying to accrue patients to studies, and if we only usedgery c November 2011
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and perhaps not completed the study.
Dr Joachim Schirren (Wiesbaden, Germany). I have 2 ques-
tions. First, you had a consensus conference about the surgical pro-
cedure from 9 centers? Second, why do you use DLCO? Currently,
I think it’s important to see the dynamics of the patient during spi-
roergometry. The last point is, if you have a patient with a DLCO
that you described, you walk with him, 3 stairs, 4 stairs, and then
you decide if you will operate. It would be interesting to see how
the DLCO was, how the physiologic status was of the patient to
steps, stairs, and, second, to see how the spiroergometry was.
Can you say something about this?
Dr Fernando. We didn’t use a stair-climbing test as such. Ac-
tually, I think it’s 35 sites that participated. The sites listed were the
top 5 accruing sites, plus some of the radiation staff who wereThe Journal of Thoracic and Carinvolved in the study design and implementation. The way the trial
developed is that we had a 2-day conference where we got together
and reviewed what the best literature out there was. We invited
some pulmonologists and radiation oncologists to the meeting as
well. Then we broke off into groups towork out the optimal criteria
that would define a high-risk group, as well as the optimal study for
these patients. So this was worked out some time ago from that
consensus conference. In fact, we used the same criteria for
Z4033, which is the radiofrequency ablation study that also re-
cently completed accrual. The only difference there was that the
surgeon had to see the patient and state that he or she didn’t think
the patient was even a candidate for sublobar resection. As you can
imagine, it took a lot longer to accrue patients to that 50-patient
trial because many of these patients were probably treated with
resection.diovascular Surgery c Volume 142, Number 5 1151
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